A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)

Trial Profile

A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs CNDO 109 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Fortress Biotech
  • Most Recent Events

    • 19 Jun 2018 Results of phase I portion (n=12) of the trial published in the journal Biology of Blood and Marrow Transplantation, according to a Fortress Biotech media release.
    • 30 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 18 May 2016 According to Fortress Biotech media release, the company announced positive data of this trial at the Innate Killer Summit 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top